Neutral
Revvity (RVTY) is divesting its China immunodiagnostics business, which represented about 6% of its revenue, to focus on higher-growth, higher-margin ...
Bullish
This article provides key financial data for Revvity, Inc. (PKN) from its balance sheet, highlighting the company's financial position as of Q1 2026. ...
Bullish
Revvity, Inc. (XETR:PKN) reported a free cash flow of 82.62 million EUR for Q1 2026. For the full year 2025, the company's free cash flow reached 43...
Neutral
Wolfe Research has initiated coverage of Revvity (RVTY) with a "Peer Perform" rating, implying that the stock is expected to perform in line with its ...
Bearish
Revvity is drawing attention in the S&P 500 due to developments in its earnings, its research tools, laboratory innovation, and diagnostic technologie...
Neutral
Revvity Inc. stock has been trading around the USD 100 mark on the NYSE, with investors closely monitoring insider activity and ownership disclosures....
Revvity (RVTY) has experienced mixed share performance recently, with the stock being roughly flat year-to-date. Despite this, analyst targets and int...
Bullish
Revvity has initiated a new share repurchase program following its latest quarterly earnings report, signaling its capital allocation priorities. The ...
Bullish
Revvity Inc. recently reported its quarterly earnings, attracting investor attention to the life-science tools and diagnostics specialist. The company...
Bullish
Revvity is gaining investor attention due to recent oncology test launches and steady demand for its diagnostic and life-science tools. The company, f...
Bullish
Revvity, a life science and diagnostics company, recently updated its quarterly figures, highlighting modest growth in core diagnostics and life scien...
Neutral
Revvity (RVTY) has experienced recent share price weakness, with the stock down 2.5% over the past day and 7% over the past week, prompting a re-evalu...
Bullish
Revvity, through its subsidiary Immunodiagnostic Systems (IDS), has received U.S. FDA 510(k) clearance for its Total Testosterone automated chemilumin...
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G/A, revealing a beneficial ownership of 10,097,663 shares, or 9.0%, of Revvity Inc. co...
Bullish
Revvity has received FDA clearance for its total testosterone automated chemiluminescence immunoassay (ChLIA) through its Immunodiagnostic Systems (ID...